Compare FINW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | CCCC |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 240.3M |
| IPO Year | 2021 | 2020 |
| Metric | FINW | CCCC |
|---|---|---|
| Price | $18.05 | $2.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.67 | $8.50 |
| AVG Volume (30 Days) | 11.8K | ★ 1.4M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $80,198,000.00 | $30,108,000.00 |
| Revenue This Year | $72.14 | N/A |
| Revenue Next Year | $47.30 | N/A |
| P/E Ratio | $17.17 | ★ N/A |
| Revenue Growth | ★ 14.76 | N/A |
| 52 Week Low | $13.49 | $1.09 |
| 52 Week High | $22.49 | $5.10 |
| Indicator | FINW | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 62.08 |
| Support Level | $17.65 | $2.29 |
| Resistance Level | $18.21 | $2.63 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 14.25 | 92.41 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.